

IN THE HOUSE OF REPRESENTATIVES

HOUSE BILL NO. 11

BY HEALTH AND WELFARE COMMITTEE

AN ACT

RELATING TO CONTROLLED SUBSTANCES; AMENDING SECTION 37-2705, IDAHO CODE, TO REVISE THE LIST OF SCHEDULE I CONTROLLED SUBSTANCES; AMENDING SECTION 37-2709, IDAHO CODE, TO PROVIDE AN EXCLUSION AND TO MAKE A TECHNICAL CORRECTION; AMENDING SECTION 37-2713, IDAHO CODE, TO REVISE THE LIST OF SCHEDULE V DRUGS AND SUBSTANCES; AND DECLARING AN EMERGENCY.

Be It Enacted by the Legislature of the State of Idaho:

SECTION 1. That Section 37-2705, Idaho Code, be, and the same is hereby amended to read as follows:

37-2705. SCHEDULE I. (a) The controlled substances listed in this section are included in schedule I.

(b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

(1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

(2) Acetylmethadol;

(3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);

(4) Allylprodine;

(5) Alphacetylmethadol (except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol, levomethadyl acetate or LAAM);

(6) Alphameprodine;

(7) Alphamethadol;

(8) Alpha-methylfentanyl;

(9) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

(10) Benzethidine;

(11) Betacetylmethadol;

(12) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);

(13) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide);

(14) Betameprodine;

(15) Betamethadol;

(16) Betaprodine;

(17) Clonitazene;

(18) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);

(19) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);

1 (20) Dextromoramide;  
 2 (1921) Diampromide;  
 3 (202) Diethylthiambutene;  
 4 (213) Difenoxin;  
 5 (224) Dimenoxadol;  
 6 (235) Dimepheptanol;  
 7 (246) Dimethylthiambutene;  
 8 (257) Dioxaphetyl butyrate;  
 9 (268) Dipipanone;  
 10 (279) Ethylmethylthiambutene;  
 11 (2830) Etonitazene;  
 12 (2931) Etoxadine;  
 13 (32) Fentanyl-related substances. "Fentanyl-related substances"  
 14 means any substance not otherwise listed and for which no exemption or  
 15 approval is in effect under section 505 of the federal food, drug, and  
 16 cosmetic act, 21 U.S.C. 355, and that is structurally related to fen-  
 17 tanyl by one (1) or more of the following modifications:  
 18 i. Replacement of the phenyl portion of the phenethyl group by any  
 19 monocycle, whether or not further substituted in or on the monocy-  
 20 cle;  
 21 ii. Substitution in or on the phenethyl group with alkyl, alkenyl,  
 22 alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;  
 23 iii. Substitution in or on the piperidine ring with alkyl,  
 24 alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino,  
 25 or nitro groups;  
 26 iv. Replacement of the aniline ring with any aromatic monocycle,  
 27 whether or not further substituted in or on the aromatic monocy-  
 28 cle; and/or  
 29 v. Replacement of the N-propionyl group by another acyl group;  
 30 (303) Furethidine;  
 31 (314) Hydroxypethidine;  
 32 (35) Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-  
 33 phenylisobutyramide);  
 34 (326) Ketobemidone;  
 35 (337) Levomoramide;  
 36 (348) Levophenacylmorphane;  
 37 (359) 3-Methylfentanyl;  
 38 (3640) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-pip-  
 39 eridinyl]-N-phenylpropanamide);  
 40 (3741) Morpheridine;  
 41 (3842) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);  
 42 (43) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);  
 43 (3944) Noracymethadol;  
 44 (405) Norlevorphanol;  
 45 (416) Normethadone;  
 46 (427) Norpipanone;  
 47 (48) Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperi-  
 48 din-4-yl) acetamide);  
 49 (49) Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-  
 50 phenethylpiperidin-4-yl) isobutyramide);

- 1        (50) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-  
2        phenethylpiperidin-4-yl) butyramide);  
3        (4351) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phen-  
4        ethyl)-4-piperidinyl] propanamide);  
5        (52) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-  
6        phenethylpiperidin-4-yl) butyramide);  
7        (4453) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);  
8        (4554) Phenadoxone;  
9        (4655) Phenampromide;  
10       (4756) Phenomorphan;  
11       (4857) Phenoperidine;  
12       (4958) Piritramide;  
13       (509) Proheptazine;  
14       (5160) Properidine;  
15       (5261) Propiram;  
16       (5362) Racemoramide;  
17       (5463) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piper-  
18       idinyl]-propanamide);  
19       (5564) Tilidine;  
20       (5665) Trimeperidine;  
21       (5766) u-47700 (3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-  
22       methylbenzamide);  
23       (67) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpen-  
24       tanamide).
- 25       (c) Any of the following opium derivatives, their salts, isomers and  
26       salts of isomers, unless specifically excepted, whenever the existence of  
27       these salts, isomers and salts of isomers is possible within the specific  
28       chemical designation:
- 29       (1) Acetorphine;  
30       (2) Acetyldihydrocodeine;  
31       (3) Benzylmorphine;  
32       (4) Codeine methylbromide;  
33       (5) Codeine-N-Oxide;  
34       (6) Cyrenorphine;  
35       (7) Desomorphine;  
36       (8) Dihydromorphine;  
37       (9) Drotebanol;  
38       (10) Etorphine (except hydrochloride salt);  
39       (11) Heroin;  
40       (12) Hydromorphanol;  
41       (13) Methyldesorphine;  
42       (14) Methyldihydromorphine;  
43       (15) Morphine methylbromide;  
44       (16) Morphine methylsulfonate;  
45       (17) Morphine-N-Oxide;  
46       (18) Myrophine;  
47       (19) Nicocodeine;  
48       (20) Nicomorphine;  
49       (21) Normorphine;  
50       (22) Pholcodine;

1 (23) Thebacon.

2 (d) Hallucinogenic substances. Any material, compound, mixture or  
3 preparation which contains any quantity of the following hallucinogenic  
4 substances, their salts, isomers and salts of isomers, unless specifically  
5 excepted, whenever the existence of these salts, isomers, and salts of iso-  
6 mers is possible within the specific chemical designation (for purposes of  
7 this paragraph only, the term "isomer" includes the optical, position and  
8 geometric isomers):

9 (1) Dimethoxyphenethylamine, or any compound not specifically  
10 excepted or listed in another schedule that can be formed from  
11 dimethoxyphenethylamine by replacement of one (1) or more hydrogen  
12 atoms with another atom(s), functional group(s) or substructure(s)  
13 including, but not limited to, compounds such as DOB, DOC, 2C-B,  
14 25B-NBOMe;

15 (2) Methoxyamphetamine or any compound not specifically excepted or  
16 listed in another schedule that can be formed from methoxyamphetamine  
17 by replacement of one (1) or more hydrogen atoms with another atom(s),  
18 functional group(s) or substructure(s) including, but not limited to,  
19 compounds such as PMA and DOM;

20 (3) 5-methoxy-3,4-methylenedioxy-amphetamine;

21 (4) 5-methoxy-N,N-diisopropyltryptamine;

22 (5) Amphetamine or methamphetamine with a halogen substitution on the  
23 benzyl ring, including compounds such as fluorinated amphetamine and  
24 fluorinated methamphetamine;

25 (6) 3,4-methylenedioxy amphetamine;

26 (7) 3,4-methylenedioxymethamphetamine (MDMA);

27 (8) 3,4-methylenedioxy-N-ethylamphetamine (also known as N-et-  
28 hyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, and N-et-  
29 hyl MDA, MDE, MDEA);

30 (9) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hyd-  
31 roxy-alpha-methyl-3,4 (methylenedioxy) phenethylamine, and N-hyd-  
32 roxy MDA);

33 (10) 3,4,5-trimethoxy amphetamine;

34 (11) 5-methoxy-N,N-dimethyltryptamine (also known as 5-methoxy-3-2[2-  
35 (dimethylamino)ethyl]indole and 5-MeO-DMT);

36 (12) Alpha-ethyltryptamine (some other names: etryptamine, 3-(2-am-  
37 inobutyl) indole);

38 (13) Alpha-methyltryptamine;

39 (14) Bufotenine;

40 (15) Diethyltryptamine (DET);

41 (16) Dimethyltryptamine (DMT);

42 (17) Ibogaine;

43 (18) Lysergic acid diethylamide;

44 (19) Marijuana;

45 (20) Mescaline;

46 (21) Parahexyl;

47 (22) Peyote;

48 (23) N-ethyl-3-piperidyl benzilate;

49 (24) N-methyl-3-piperidyl benzilate;

50 (25) Psilocybin;

1 (26) Psilocyn;

2 (27) Tetrahydrocannabinols or synthetic equivalents of the substances  
3 contained in the plant, or in the resinous extractives of Cannabis, sp.  
4 and/or synthetic substances, derivatives, and their isomers with simi-  
5 lar chemical structure such as the following:

6 i. Tetrahydrocannabinols:

7 a.  $\Delta^1$  cis or trans tetrahydrocannabinol, and their opti-  
8 cal isomers, excluding dronabinol in sesame oil and encapsu-  
9 lated in either a soft gelatin capsule or in an oral solution  
10 in a drug product approved by the U.S. Food and Drug Adminis-  
11 tration.

12 b.  $\Delta^6$  cis or trans tetrahydrocannabinol, and their optical  
13 isomers.

14 c.  $\Delta^{3,4}$  cis or trans tetrahydrocannabinol, and its optical  
15 isomers. (Since nomenclature of these substances is not in-  
16 ternationally standardized, compounds of these structures,  
17 regardless of numerical designation of atomic positions are  
18 covered.)

19 d. [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2methyl-  
20 octan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-  
21 1-ol)], also known as 6aR-trans-3-(1,1-dimethylhep-  
22 tyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-  
23 dibenzo[b,d]pyran-9-methanol (HU-210) and its geometric  
24 isomers (HU211 or dexanabinol).

25 ii. The following synthetic drugs:

26 a. Any compound structurally derived from (1H-indole-3-  
27 yl)(cycloalkyl, cycloalkenyl, aryl)methanone, or (1H-in-  
28 dole-3-yl)(cycloalkyl, cycloalkenyl, aryl)methane, or  
29 (1H-indole-3-yl)(cycloalkyl, cycloalkenyl, aryl), methyl  
30 or dimethyl butanoate, amino-methyl (or dimethyl)-1-oxobu-  
31 tan-2-yl) carboxamide by substitution at the nitrogen atoms  
32 of the indole ring or carboxamide to any extent, whether or  
33 not further substituted in or on the indole ring to any ex-  
34 tent, whether or not substituted to any extent in or on the  
35 cycloalkyl, cycloalkenyl, aryl ring(s) (substitution in the  
36 ring may include, but is not limited to, heteroatoms such as  
37 nitrogen, sulfur and oxygen).

38 b. Any compound structurally derived from 3-(1-naph-  
39 thoyl)pyrrole by substitution at the nitrogen atom of the  
40 pyrrole ring to any extent, whether or not further substi-  
41 tuted in the pyrrole ring to any extent, whether or not  
42 substituted in the naphthyl ring to any extent.

43 c. Any compound structurally derived from 1-(1-naphthyl-  
44 methyl)indene by substitution at the 3-position of the in-  
45 dene ring to any extent, whether or not further substituted  
46 in the indene ring to any extent, whether or not substituted  
47 in the naphthyl ring to any extent.

48 d. Any compound structurally derived from 3-phenyl-  
49 lacetylindole by substitution at the nitrogen atom of the  
50 indole ring to any extent, whether or not further substi-

1           tuted in the indole ring to any extent, whether or not sub-  
2           stituted in the phenyl ring to any extent.

3           e. Any compound structurally derived from 2-(3-hydroxycy-  
4           clohexyl)phenol by substitution at the 5-position of the  
5           phenolic ring to any extent, whether or not substituted in  
6           the cyclohexyl ring to any extent.

7           f. Any compound structurally derived from 3-(benzoyl)in-  
8           dole structure with substitution at the nitrogen atom of  
9           the indole ring to any extent, whether or not further sub-  
10          stituted in the indole ring to any extent and whether or not  
11          substituted in the phenyl ring to any extent.

12          g. [2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrol-  
13          o[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone  
14          (WIN-55,212-2).

15          h. 3-dimethylheptyl-11-hydroxyhexahydrocannabinol (HU-  
16          243).

17          i. [(6S, 6aR, 9R, 10aR)-9-hydroxy-6-methyl-3-[(2R)-  
18          5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahy-  
19          drophenanthridin-1-yl]acetate (CP 50,5561).

20          (28) Ethylamine analog of phencyclidine: N-ethyl-1-phenylcy-  
21          clohexylamine (1-phenylcyclohexyl) ethylamine; N-(1-phenylcy-  
22          clohexyl) ethylamine, cyclohexamine, PCE;

23          (29) Pyrrolidine analog of phencyclidine: 1-(phenylcyclohexyl) -  
24          pyrrolidine, PCPy, PHP;

25          (30) Thiophene analog of phencyclidine 1-[1-(2-thienyl)-cyclohexyl]-  
26          piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP;

27          (31) 1-[1-(2-thienyl) cyclohexyl] pyrrolidine another name: TCPy;

28          (32) Spores or mycelium capable of producing mushrooms that contain  
29          psilocybin or psilocin.

30          (e) Unless specifically excepted or unless listed in another schedule,  
31          any material, compound, mixture or preparation which contains any quantity  
32          of the following substances having a depressant effect on the central ner-  
33          vous system, including its salts, isomers, and salts of isomers whenever the  
34          existence of such salts, isomers, and salts of isomers is possible within the  
35          specific chemical designation:

36                (1) Gamma hydroxybutyric acid (some other names include GHB; gam-  
37                ma-hydroxybutyrate, 4-hydroxybutyrate; 4-hydroxybutanoic acid; sod-  
38                ium oxybate; sodium oxybutyrate);

39                (2) Flunitrazepam (also known as "R2," "Rohypnol");

40                (3) Mecloqualone;

41                (4) Methaqualone.

42          (f) Stimulants. Unless specifically excepted or unless listed in an-  
43          other schedule, any material, compound, mixture, or preparation which con-  
44          tains any quantity of the following substances having a stimulant effect on  
45          the central nervous system, including its salts, isomers, and salts of iso-  
46          mers:

47                (1) Aminorex (some other names: aminoxaphen, 2-amino-5-phenyl-2-ox-  
48                azoline, or 4,5-dihydro-5-phenyl-2-oxazolamine);

49                (2) Cathinone (some other names: 2-amino-1-phenol-1-propanone, alp-  
50                ha-aminopropiophenone, 2-aminopropiophenone and norephedrone);

1 (3) Substituted cathinones. Any compound, except bupropion or com-  
2 pounds listed under a different schedule, structurally derived from  
3 2-aminopropan-1-one by substitution at the 1-position with either  
4 phenyl, naphthyl or thiophene ring systems, whether or not the compound  
5 is further modified in any of the following ways:

6 i. By substitution in the ring system to any extent with alkyl,  
7 alkylendioxy, alkoxy, haloalkyl, hydroxyl or halide sub-  
8 stituents, whether or not further substituted in the ring system  
9 by one (1) or more other univalent substituents;

10 ii. By substitution at the 3-position with an acyclic alkyl sub-  
11 stituent;

12 iii. By substitution at the 2-amino nitrogen atom with alkyl,  
13 dialkyl, benzyl or methoxybenzyl groups, or by inclusion of the  
14 2-amino nitrogen atom in a cyclic structure.

15 (4) Fenethylamine;

16 (5) Methcathinone (some other names: 2-(methyl-amino)-propio-  
17 phenone, alpha-(methylamino)-propio-phenone, N-methylcathinone, AL-  
18 464, AL-422, AL-463 and UR1423);

19 (6) (+/-)cis-4-methylaminorex [(+/-)cis-4,5-dihydro-4-methyl-5-  
20 phenyl-2-oxazolamine];

21 (7) N-benzylpiperazine (also known as: BZP, 1-benzylpiperazine);

22 (8) N-ethylamphetamine;

23 (9) N,N-dimethylamphetamine (also known as: N,N-alpha-trimethyl-ben-  
24 zeneethanamine).

25 SECTION 2. That Section 37-2709, Idaho Code, be, and the same is hereby  
26 amended to read as follows:

27 37-2709. SCHEDULE III. (a) Schedule III shall consist of the drugs and  
28 other substances, by whatever official name, common or usual name, chemical  
29 name, or brand name designated, listed in this section.

30 (b) Stimulants. Unless specifically excepted or unless listed in  
31 another schedule, any material, compound, mixture, or preparation which  
32 contains any quantity of the following substances having a stimulant ef-  
33 fect on the central nervous system, including its salts, isomers, (whether  
34 optical or geometric), and salts of such isomers whenever the existence of  
35 such salts, isomers, and salts of isomers is possible within the specific  
36 chemical designation:

37 (1) Those compounds, mixtures, or preparations in dosage unit form con-  
38 taining any stimulant substances listed in schedule II which compounds,  
39 mixtures, or preparations were listed as excepted compounds under 21  
40 CFR 1308.32, and any other drug of the quantitative composition shown in  
41 that list for those drugs or which is the same except that it contains a  
42 lesser quantity of controlled substances.

43 (2) Benzphetamine;

44 (3) Chlorphentermine;

45 (4) Clortermine;

46 (5) Phendimetrazine.

47 (c) Depressants. Unless listed in another schedule, any material, com-  
48 pound, mixture, or preparation which contains any quantity of the following

1 substances having a potential for abuse associated with a depressant effect  
2 on the central nervous system:

- 3 (1) Any compound, mixture or preparation containing:  
4 i. Amobarbital;  
5 ii. Secobarbital;  
6 iii. Pentobarbital or any salt thereof and one (1) or more other  
7 active medicinal ingredients which are not listed in any schedule.
- 8 (2) Any suppository dosage form containing:  
9 i. Amobarbital;  
10 ii. Secobarbital;  
11 iii. Pentobarbital or any salt of any of these drugs and approved  
12 by the Food and Drug Administration for marketing only as a suppos-  
13 itory.
- 14 (3) Any substance which contains any quantity of a derivative of barbi-  
15 turic acid or any salt thereof, including, but not limited to:  
16 i. Aprobarbital;  
17 ii. Butobarbital (secbutobarbital);  
18 iii. Butalbital, excluding drug products exempted by the federal  
19 drug enforcement administration (DEA);  
20 iv. Butobarbital (butethal);  
21 v. Talbutal;  
22 vi. Thiamylal;  
23 vii. Thiopental;  
24 viii. Vinbarbital.
- 25 (4) Chlorhexadol;  
26 (5) Embutramide;  
27 (6) Any drug product containing gamma hydroxybutyric acid, including  
28 its salts, isomers, and salts of isomers, for which an application is  
29 approved under section 505 of the federal food, drug, and cosmetic act;  
30 (7) Ketamine, its salts, isomers, and salts of isomers-  
31 7285. (Some other names for ketamine: (+/-)-2-(2-chlorophenyl)-2-  
32 (methylamino)-cyclohexanone).
- 33 (8) Lysergic acid;  
34 (9) Lysergic acid amide;  
35 (10) Methyprylon;  
36 (11) Perampanel, and its salts, isomers and salts of isomers;  
37 (12) Sulfondiethylmethane;  
38 (13) Sulfonethylmethane;  
39 (14) Sulfonmethane;  
40 (15) Tiletamine and zolazepam or any salt thereof.
- 41 (d) Nalorphine.  
42 (e) Narcotic drugs. Unless specifically excepted or unless listed in  
43 another schedule:  
44 (1) Any material, compound, mixture, or preparation containing limited  
45 quantities of any of the following narcotic drugs, or any salts thereof:  
46 (i) Not more than 1.8 grams of codeine, or any of its salts, per  
47 100 milliliters or not more than 90 milligrams per dosage unit,  
48 with an equal or greater quantity of an isoquinoline alkaloid of  
49 opium;



- 1 (ii) Not more than 1.8 grams of codeine, or any of its salts, per  
 2 100 milliliters or not more than 90 milligrams per dosage unit,  
 3 with one (1) or more active, nonnarcotic ingredients in recognized  
 4 therapeutic amounts;
- 5 (iii) Not more than 1.8 grams of dihydrocodeine, or any of its  
 6 salts, per 100 milliliters or not more than 90 milligrams per  
 7 dosage unit, with one (1) or more active, nonnarcotic ingredients  
 8 in recognized therapeutic amounts;
- 9 (iv) Not more than 300 milligrams of ethylmorphine, or any of  
 10 its salts, per 100 milliliters or not more than 15 milligrams per  
 11 dosage unit, with one (1) or more ingredients in recognized thera-  
 12 peutic amounts;
- 13 (v) Not more than 500 milligrams of opium per 100 milliliters  
 14 or per 100 grams, or not more than 25 milligrams per dosage unit,  
 15 with one (1) or more active, nonnarcotic ingredients in recognized  
 16 therapeutic amounts;
- 17 (vi) Not more than 50 milligrams of morphine, or any of its salts,  
 18 per 100 milliliters or per 100 grams with one (1) or more active,  
 19 nonnarcotic ingredients in recognized therapeutic amounts.
- 20 (2) Any material, compound, mixture, or preparation containing any of  
 21 the following narcotic drugs or their salts, as set forth below:
- 22 (i) Buprenorphine.
- 23 (ii) [Reserved].
- 24 (f) Anabolic steroids and human growth hormones. Any drug or hormonal  
 25 substance, chemically and pharmacologically related to testosterone (other  
 26 than estrogens, progestins and corticosteroids) that promotes muscle growth  
 27 including any salt, ester or isomer of a drug or substance listed in this  
 28 ~~paragraph~~ subsection, if that salt, ester or isomer promotes muscle growth.
- 29 (1) 13beta-ethyl-17beta-hydroxygon-4-en-3-one;
- 30 (2) 17alpha-methyl-3alpha, 17beta-dihydroxy-5alpha-androstane;
- 31 (3) 17alpha-methyl-3beta, 17beta-dihydroxy-5alpha-androstane;
- 32 (4) 17alpha-methyl-3beta, 17beta-dihydroxyandrost-4-ene;
- 33 (5) 17alpha-methyl-4-hydroxynandrolone;
- 34 (6) 17alpha-methyl-delta1-dihydrotestosterone;
- 35 (7) 19-nor-4-androstenediol;
- 36 (8) 19-nor-4-androstenedione;
- 37 (9) 19-nor-4,9(10)-androstadienedione;
- 38 (10) 19-nor-5-androstenediol;
- 39 (11) 19-nor-5-androstenedione;
- 40 (12) 1-androstenediol;
- 41 (13) 1-androstenedione;
- 42 (14) 3alpha,17beta-dihydroxy-5alpha-androstane;
- 43 (15) 3beta,17beta-dihydroxy-5alpha-androstane;
- 44 (16) 4-androstenediol;
- 45 (17) 4-androstenedione;
- 46 (18) 4-hydroxy-19-nortestosterone;
- 47 (19) 4-hydroxytestosterone;
- 48 (20) 5-androstenediol;
- 49 (21) 5-androstenedione;
- 50 (22) Androstenedione;

- 1 (23) Bolasterone;
- 2 (24) Boldenone;
- 3 (25) Boldione;
- 4 (26) Calusterone;
- 5 (27) Chlorotestosterone (4-chlorotestosterone);
- 6 (28) Clostebol;
- 7 (29) Dehydrochlormethyltestosterone;
- 8 (30) Delta1-dihydrotestosterone;
- 9 (31) Desoxymethyltestosterone;
- 10 (32) Dihydrotestosterone (4-dihydrotestosterone);
- 11 (33) Drostanolone;
- 12 (34) Ethylestrenol;
- 13 (35) Fluoxymesterone;
- 14 (36) Formebolone;
- 15 (37) Furazabol;
- 16 (38) Human growth hormones;
- 17 (39) Mestanolone;
- 18 (40) Mesterolone;
- 19 (41) Methandienone;
- 20 (42) Methandranone;
- 21 (43) Methandriol;
- 22 (44) Methandrostenolone;
- 23 (45) Methasterone (2a, 17a-dimethyl-5a-androstan-17 $\beta$ -ol-3-one);
- 24 (46) Methenolone;
- 25 (47) Methyldienolone;
- 26 (48) Methyltestosterone;
- 27 (49) Methyltrienolone;
- 28 (50) Mibolerone;
- 29 (51) Nandrolone;
- 30 (52) Norbolethone;
- 31 (53) Norclostebol;
- 32 (54) Norethandrolone;
- 33 (55) Normethandrolone;
- 34 (56) Oxandrolone;
- 35 (57) Oxymesterone;
- 36 (58) Oxymetholone;
- 37 (59) Prostanazol (17 $\beta$ -hydroxy-5a-androstano[3,2-c]pyrazole);
- 38 (60) Stanolone;
- 39 (61) Stanozolol;
- 40 (62) Stenbolone;
- 41 (63) Testolactone;
- 42 (64) Testosterone;
- 43 (65) Testosterone cypionate;
- 44 (66) Testosterone enanthate;
- 45 (67) Testosterone propionate;
- 46 (68) Tetrahydrogestrinone;
- 47 (69) Trenbolone.

48 Anabolic steroids that are expressly intended for administration  
49 through implants or injection to cattle or other nonhuman species, and that  
50 are approved by the federal Food and Drug Administration for such use, shall

1 not be classified as controlled substances under this act and shall not be  
2 governed by its provisions.

3 In addition to the penalties prescribed in article IV of the uniform  
4 controlled substances act, any person shall be guilty of a felony who pre-  
5 scribes, dispenses, supplies, sells, delivers, manufactures or possesses  
6 with the intent to prescribe, dispense, supply, sell, deliver or manufac-  
7 ture anabolic steroids or any other human growth hormone for purposes of  
8 enhancing performance in an exercise, sport or game or hormonal manipulation  
9 intended to increase muscle mass, strength or weight without a medical ne-  
10 cessity as determined by a physician.

11 (g) Hallucinogenic substances.

12 (1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft  
13 gelatin capsule in the federal Food and Drug Administration ap-  
14 proved product -- 7369. (Some other names for dronabinol: (6aR-  
15 trans) -6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo  
16 [b,d]pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol).

17 (h) The board may except by rule any compound, mixture, or preparation  
18 containing any stimulant or depressant substance listed in subsection (b)  
19 or (c) of this section from the application of all or any part of this act if  
20 the compound, mixture, or preparation contains one (1) or more active medic-  
21 inal ingredients not having a stimulant or depressant effect on the central  
22 nervous system, and if the admixtures are included therein in combinations,  
23 quantity, proportion, or concentration that vitiate the potential for abuse  
24 of the substances which have a stimulant or depressant effect on the central  
25 nervous system.

26 SECTION 3. That Section 37-2713, Idaho Code, be, and the same is hereby  
27 amended to read as follows:

28 37-2713. SCHEDULE V. (a) Schedule V shall consist of the drugs and  
29 other substances, by whatever official name, common or usual name, chemical  
30 name, or brand name designated, listed in this section.

31 (b) Narcotic drugs. Unless specifically excepted or unless listed in  
32 another schedule, any material, compound, mixture, or preparation contain-  
33 ing any of the following narcotic drugs and their salts, as set forth below.

34 (c) Narcotic drugs containing nonnarcotic active medicinal ingredi-  
35 ents. Any compound, mixture, or preparation containing any of the follow-  
36 ing limited quantities of narcotic drugs or salts thereof, which shall in-  
37 clude one (1) or more nonnarcotic active medicinal ingredients in sufficient  
38 proportion to confer upon the compound, mixture, or preparation, valuable  
39 medicinal qualities other than those possessed by the narcotic drug alone:

40 (1) Not more than 200 milligrams of codeine per 100 milliliters or per  
41 100 grams;

42 (2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters  
43 or per 100 grams;

44 (3) Not more than 100 milligrams of ethylmorphine per 100 milliliters  
45 or per 100 grams;

46 (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25  
47 micrograms of atropine sulfate per dosage unit;

48 (5) Not more than 100 milligrams of opium per 100 milliliters or per 100  
49 grams;

1 (6) Not more than 0.5 milligrams difenoxin and not less than 25 micro-  
2 grams of atropine sulfate per dosage unit.

3 (d) Other substances. Unless specifically excepted or unless listed  
4 in another schedule, any material, compound, mixture or preparation which  
5 contains any quantity of the following substances, including its salts:

6 (1) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]bu-  
7 tanamide) (also referred to as BRV; UCB-34714; Briviact) (including its  
8 salts);

9 (2) Ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic  
10 acid ethyl ester]-2779;

11 (3) Lacosamide;

12 (4) Pregabalin;

13 (5) Pyrovalerone.

14 (e) Approved cannabidiol drugs. A drug product in finished dosage  
15 formulation that has been approved by the U.S. food and drug administration  
16 that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclo-  
17 hexen-1-yl]-5-pentyl-1,3- benzenediol) derived from cannabis and no more  
18 than 0.1 percent (w/w) residual tetrahydrocannabinols.

19 SECTION 4. An emergency existing therefor, which emergency is hereby  
20 declared to exist, this act shall be in full force and effect on and after its  
21 passage and approval.